Reported 2 days ago
Sanofi, the French pharmaceutical giant, has agreed to acquire US-based Blueprint Medicines Corporation for $9.1 billion, paying $129 per share. This acquisition aims to strengthen Sanofi's rare immunology portfolio by adding the drug Ayvakit/Ayvakyt, which is used for systemic mastocytosis, alongside a promising pipeline of other immunology treatments. The deal reinforces Sanofi's position in the immunology sector and reflects its strategy to lead in this field.
Source: YAHOO